Assessment of the anti-obesity effects of the TNP-470 analog CKD-732

Yoo Mee Kim, Juan Ji An, Yong Jun Jin, Yumie Rhee, Bong Soo Cha, Hyun Chul Lee, Sung Kil Lim

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

The systemic treatment with angiogenesis inhibitor has been shown to result in weight reduction and adipose tissue loss in various models of obesity. To verify the mechanism of CKD-732 (TNP-470 analog) against obesity, we evaluated CKD-732's peripheral and central anti-obesity effects. CKD-732 was injected subcutaneously (s.c.) for 7 days in various animal models and intracerebroventricularly (i.c.v.) in arcuate nucleus (ARC) lesion mice, ob/ob mice, and normal littermates. Modulation of the hypothalamic neuropeptide mRNAs after i.c.v. injection was evaluated in ARC lesion mice and normal littermates. A conditioned taste aversion (CTA) was performed using lithium chloride (LiCl) as a positive control agent in Long-Evans Tokushima Otsuka and Otsuka Long-Evans Tokushima fatty (OLETF) rats. As a result, 7 days of CKD-732 s.c. injection reduced the cumulative food intake and the body weight significantly in both treated obese (e.g. 114.8±13.4 g vs 170.7±20.6 g, 7.9±0.5% decrease vs 0.3±2.2% decrease; in treated OLETF rat versus control OLETF rat, P<0.01 respectively) and non-obese models. Epididymal and mesenteric fat pads, and the size of adipocytes were significantly decreased in treated rats. A single i.c.v. injection decreased food intake and body weight in ARC lesion mice and ob/ob mice but not in normal littermates. Unexpectedly, the hypothalamic neuropeptide mRNAs were not altered by single i.c.v. injection. CKD-732 also induced a dose-dependent CTA comparable with LiCI injection, which is a commonly used agent to produce a CTA. In conclusion, CKD-732 causes significant body weight and appetite reduction, possibly by decreasing adiposity directly and inducing central anorexia, which is partly explained by a CTA. These results should be carefully verified to assess the utility of CKD-732 as an anti-obesity drug.

Original languageEnglish
Pages (from-to)455-465
Number of pages11
JournalJournal of molecular endocrinology
Volume38
Issue number3-4
DOIs
Publication statusPublished - 2007 Mar 1

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Endocrinology

Fingerprint Dive into the research topics of 'Assessment of the anti-obesity effects of the TNP-470 analog CKD-732'. Together they form a unique fingerprint.

  • Cite this